-
This meta-analysis was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement (Supplementary Table S1 available in www.besjournal.com) [18].
Table S1. PRISMA 2020 checklist
Section and topic Item Checklist item Location
where item
is reportedTITLE Title 1 Identify the report as a systematic review. 2 ABSTRACT Abstract 2 See the PRISMA 2020 for Abstracts checklist. 2 INTRODUCTION Rationale 3 Describe the rationale for the review in the context of existing knowledge. 2 Objectives 4 Provide an explicit statement of the objective(s) or question(s) the review addresses. 3 METHODS Eligibility criteria 5 Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. 3 Information sources 6 Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted. 3 Search strategy 7 Present the full search strategies for all databases, registers and websites, including any filters and limits used. 3 Selection process 8 Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. 3 Data collection process 9 Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. 3 Data items 10a List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect. 3 10b List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information. 3 Study risk of bias assessment 11 Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process. 4 Effect measures 12 Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results. 4 Synthesis methods 13a Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)). 13b Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions. 4 13c Describe any methods used to tabulate or visually display results of individual studies and syntheses. 4 13d Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. 4 13e Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression). 4 13f Describe any sensitivity analyses conducted to assess robustness of the synthesized results. 4 Reporting bias assessment 14 Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases). 4 Certainty assessment 15 Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. 4 RESULTS Study selection 16a Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram. 5 16b Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded. Study characteristics 17 Cite each included study and present its characteristics. 7–8 Risk of bias in studies 18 Present assessments of risk of bias for each included study. 5 Results of individual studies 19 For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots. 9, 11 Results of syntheses 20a For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies. 5 20b Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect. 9 20c Present results of all investigations of possible causes of heterogeneity among study results. 9 20d Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results. 11 Reporting biases 21 Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed. 12 Certainty of evidence 22 Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed. 11 DISCUSSION Discussion 23a Provide a general interpretation of the results in the context of other evidence. 12 23b Discuss any limitations of the evidence included in the review. 13 23c Discuss any limitations of the review processes used. 13 23d Discuss implications of the results for practice, policy, and future research. 13 OTHER INFORMATION Registration and protocol 24a Provide registration information for the review, including register name and registration number, or state that the review was not registered. 24b Indicate where the review protocol can be accessed, or state that a protocol was not prepared. 24c Describe and explain any amendments to information provided at registration or in the protocol. Support 25 Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review. Competing interests 26 Declare any competing interests of review authors. Availability of data, code and other materials 27 Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. Note. From: Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71.For more information, visit: http://www.prisma-statement.org/ -
A systematic search was done on the scientific databases, including ISI Web of Science, Embase, PubMed, and the Cochrane Library, for extracting the relevant articles published from the inception to June 7, 2021. To explore the impact of 24-h urinary sodium excretion on CV events, we used a combination of keywords related to CV events and urinary sodium. Keywords associated with dietary sodium and potassium intake were also searched to avoid missing out on the studies that met our subject’s criteria. In addition, the reference list was manually searched for the included studies. Detailed strategies for searching are shown in Supplementary Materials (available in www.besjournal.com).
-
Two authors independently reviewed the studies, and any conflicts were resolved with the common consensus. First, the selection was conducted based on the title and abstract. Then the full texts of studies were reviewed for conforming our subject. Inclusion criteria: 1) full-texts in English; 2) cohort studies; 3) studies assessing the relationship of 24-h urinary sodium excretion with CV risk; 4) studies assessing 24-h urinary sodium excretion as exposure in at least three categories; 5) studies with the endpoints of either combined or single CV events (incidence and mortality); 6) studies providing adjusted effect estimates and 95% confidence intervals (CIs).
Exclusion criteria: 1) non-English articles; 2) cross-sectional studies; 3) animal studies; 4) studies including kidney diseases patients; 5) studies with un-adjusted effect estimates. In addition, if multiple studies were from the same population, we included the longest follow-up study.
-
The following dataset was retrieved independently by the two authors: the first author’s name, publication year, study region, study design, follow-up time, number of participants and cases, participant’s gender, age at baseline, method of measuring 24-h urinary sodium excretion, assessment of exposure, outcome definition, covariates adjustment in the multivariate model, the indicator of effect estimates and other relevant characteristics. If the included studies reported models with different covariates adjustment, the meta-analysis selected the model with the most adjusted covariates.
-
The Newcastle-Ottawa Quality Assessment Scale (NOS) was employed to estimate studies quality. The highest score was 9, and the lowest score was 0 for any study. Moreover, the studies that scored more than 7 were considered high quality.
-
The relative risks (RRs) with 95% CIs were used to calculate the effect size in studies, and then they were converted to natural logarithms to normalize their distribution. The hazard ratios (HRs) were considered equal to the RRs. If the reference category was not the lowest, we took the lowest category as the reference and then recalculated the effect estimates [19].
The association between 24-h urinary sodium excretion and the risk of CV events was evaluated via dividing sodium excretion into relatively low-level excretion and high-level excretion. Though the World Health Organization (WHO) recommended a sodium intake of < 2 g/d [20] and the Institute of Medicine (IOM) defined a tolerable upper sodium intake level of 2.3 g/d [21], few people reached the recommended level. Global mean sodium intake was 3.95 g/d in 2010 [22], and the mean sodium excretion ranged from 3 to 4.9 g/d in the studies that included in this meta-analysis. Therefore, the cut-off point of 4 g was used in our meta-analysis, low-level excretion was defined as < 4 g and high-level excretion ≥ 4 g in our study. In one study, dose groups with medians higher than the cut-off point were classified as high-level, otherwise low-level. If studies reported sodium excretion in moles, it was converted into grams (1 mol = 23 g). In one study, the fixed-effects model combined the RRs of different dose groups. The random-effects model summarizes the total RRs between the included studies [23]. Sensitivity analysis was employed by removing one study to assess the potential effect of a single study on the pooled RR. Some studies included heart failure as an outcome, sensitivity analysis was conducted by excluding these studies. The study by Ma et al. was excluded due to duplication with our included population cohort, sensitivity analysis was also conducted by including this study [24]. The heterogeneity between the included studies was computed adopting Cochran’s Q test and I2 statistic. Studies with values of I2 statistics less than 30% were considered to have no heterogeneity, whereas studies with more than 75% had notable heterogeneity or otherwise showed moderate heterogeneity [25]. To explain the observed heterogeneity, we performed subgroup analysis based on the follow-up duration, sample size, population information, method of urine collection, study quality, and adjusted confounders such as blood pressure or hypertension, potassium excretion. The funnel plot, Egger’s test [26], and Begg’s test [27] were used to estimate the publication bias.
Then the dose-response meta-analysis was performed to explore the possible dose-response association, using the method proposed by Greenland, Longnecker, and Orsini [28, 29]. The method requires the number of cases and non-cases, or person-years in categories of urinary sodium excretion and the reported mean for every category of exposures. If the mean for each category of exposures was not reported, it was replaced with the median; otherwise, the midpoint in the exposure category was used. For the open category (highest and lowest), 20% high or low was calculated from the nearest cut-off point. Next, the non-linear relationship of urinary sodium excretion and CV events risk was estimated using the restricted cubic splines model with three knots at fixed percentiles (5%, 50%, and 95%)[30]. In contrast, the generalized least-squares regression was used to fit the model [29]. Finally, we pooled the effect estimates using the two-stage approach's random-effects models. Whenever the second spline coefficient was equal to zero, the non-linear P-value for the dose-response meta-analysis was computed. The Stata 14.0 and Stata 16.0 software (StataCorp, College Station, Texas 77845 USA) were used for the statistical analysis.
-
A total of 9,495 records were searched by the online databases and the references of the relevant studies. After excluding the duplicates and examining studies by titles and abstracts, 90 articles were included for assessing the full text. According to the inclusion and exclusion criteria, finally, 9 studies were eventually included. Selection details are described in Figure 1.
-
The characteristics of the 9 included studies are shown in Table 1 [9, 10, 12, 14, 31-35]. Further information (the categories of urinary sodium excretion in original studies, the original effect size and transformed effect size, and covariates/factors adjusted in multivariate model) is shown in Supplementary Table S2 available in www.besjournal.com. The studies included in the meta-analysis were published between 2011 and 2021. A total of 645,006 participants with a median follow-up period of 4.7 to 19.1 years were recruited in our study. Two studies were carried out in the United States [10, 12], two in the United Kingdom [32, 35], one in the Netherlands [31], one in Finland [33], one in China [34], and two multi-centric studies with recruited subjects from several countries [9, 14]. For urinary sodium excretion assessment, 4 studies collected the 24-h urine samples [10, 12, 31, 33], 2 collected the morning fasting urine samples [9, 14], 2 collected the spot urine samples [32, 35], whereas the 1 collected the overnight urine [34]. The mean score of included studies for NOS was 8 (Supplementary Table S3 available in www.besjournal.com). Moreover, most studies results were greater than 7 [10, 31-35]. One in nine studies reported data on men and women, respectively [35]. The covariates adjusted in most multivariate models were the baseline age, body mass index (BMI), ethnicity/race, sex, alcohol intake, smoking, blood pressure or hypertension, and blood fat level. The outcome definition of studies included total CVD, CVD death, heart failure, coronary heart disease, all caused mortality, atrial fibrillation, and atrial flutter. The daily urinary sodium excretion ranged from 1.265 to 9.4 g. Besides, all studies reported HR. Three studies reported a J-shaped relationship between calculated sodium excretion and risk of CV events [9, 14, 33], 2 studies reported a U-shaped [32, 35], and 2 studies reported a linear association [10, 34]. On the contrary, 2 studies suggested no significant effect of sodium excretion upon CV events [12, 31].
Table 1. Characteristics of the included studies in this Meta-Analysis
Author, year Country Follow-up (years) Subjects/
events (n)Age (y) Gender Methods
of Na
measurementStudy population Outcome definition Martin J. O’Donnell, 2011[9] 40 countries 4.7 28,880/
4,72966.52 ±
7.22men/
womencollected morning fasting urine samples participants in ONTARGET and the TRANSCEND trials composite outcome (CV mortality, myocardial infarction, stroke, and hospitalization for CHF) Roman Pfister, 2013[32] the United Kingdom 12.9 19,857/
1,21058.0 ±
9.2men/
womencollected casual urine specimen general population heart failure Michel M. Joosten, 2013[31] the
Netherlands10.5 (IQR: 9.9−10.8) 7,543/
45228−75 men/
womencollected 24-h urine samples general population CHD was defined as incident cardiac morbidity and mortality (including myocardial infarction, acute and subacute ischemic heart disease, and coronary artery bypass grafting or percutaneous transluminal coronary angioplasty) Nancy R. Cook, 2014[10] the United States 5 2,312/
19331−50 men/
womencollected 24-h urine samples general population CVD or CVD death, including myocardial infarction, stroke, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, or death from cardiovascular disease Pamela Singer, 2014[12] the United States 18.6 3,505/
39952.4 ±
9.9men/
womencollected 24-h urine samples participants were individuals in a union-sponsored, worksite hypertension program in New York City between 1978 and 1999 coronary artery disease, including MI, ischemic heart disease, heart failure, and hypertensive heart disease Martin O’Donnell, 2019[14] 628 urban
and rural communities
in low, middle,
and high
income countries8.2 103,200/
7,88435−70 men/
womencollected morning fasting midstream urine sample general population the primary composite outcome was all caused mortality or myocardial infarction or stroke or heart failure Matti A. Vuori, 2020[33] Finland 14 4,517/
42445.4 ±
11.4men/
womencollected 24-h urine samples general population CVD was defined as the onset of CHD, stroke, or heart failure Wuopio J,
2020[35]the United Kingdom 8.2 ± 1.0 215,535/
3,75140−69 men collected midstream spot urine samples general population atrial fibrillation or atrial flutter 257,545/
2,221women Yi-Jie Wang, 2021[34] China 19.1 (IQR: 7.4−21.4) 2,112/
27954 ±
12men/
womenrecorded the sleep time and calculated the 24-h urine amount from sleep time and morning voiding urine general population Incident CVD events, including CHD and stroke Note. 24 h UNaE: 24 h urinary sodium excretion; CV: cardiovascular; CHD: coronary heart disease; CVD: cardiovascular disease; CHF: congestive heart failure; ONTARGET: Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial; TRANSCEND: Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease. -
The association between the high and the low levels of sodium excretion with the risk of CV events are shown in Figure 2. The total RR was 0.91 (95% CI: 0.86, 0.96; I2 = 16.82%) and 1.01 (95% CI: 0.91, 1.12; I2 = 84.25%) for the association between low-level sodium excretion (vs. the lowest of 1.265 g) and the high-level sodium excretion (vs. the lowest of 1.265 g) with the risk of CV events, respectively. However, significant heterogeneity between the studies was found (P = 0.01) in the high-level group. Therefore, subgroup analyses were carried out based on the follow-up duration, sample size, population information, method of urine collection, study quality, and adjusted confounders such as blood pressure or hypertension, potassium excretion (Table 2). Further, the subgroup of sample size and method of urine collection could explain the part of the heterogeneity.
Figure 2. (A) Forest Plot of relative risks (RRs) and 95% Confidence Intervals (CIs) for the association between low-level sodium excretion (< 4 g/d) and the risk of CV events. (B) RRs and 95% CIs for the association between high-level sodium excretion (≥ 4 g/d) and the risk of CV events.
Table 2. Subgroup analysis of different levels of sodium excretion and the risk of CV events
Subgroups No. of studies Low level High level Pooled RR (95% CI) P value I² (%) P value for
heterogeneityPooled RR (95% CI) P value I² (%) P value for
heterogeneityFollow-up duration < 10 years 4 0.910
(0.866, 0.958)0.0003 < 0.01 0.9611 0.926
(0.895, 0.957)< 0.0001 0.01 0.2904 > 10 years 5 0.947
(0.821, 1.093)0.4575 54.77 0.0481 1.093
(0.898, 1.329)0.3759 68.49 0.0037 Sample size < 10,000 5 1.027
(0.912, 1.156)0.6632 < 0.01 0.9789 1.228
(1.070, 1.410)0.0035 < 0.01 0.5886 > 10,000 4 0.886
(0.836, 0.940)0.0001 27.48 0.1930 0.918
(0.889, 0.948)< 0.0001 0.02 0.6090 Conducted in general population Yes 7 0.912
(0.843, 0.986)0.0207 42.63 0.1654 1.049
(0.902, 1.220)0.5358 91.08 0.0021 No 2 0.932
(0.834, 1.042)0.2162 < 0.01 0.4745 0.943
(0.861, 1.033)0.2062 < 0.01 0.7316 Method of urine collection Collected 24-h urine samples 4 1.042
(0.911, 1.192)0.5489 < 0.01 0.9721 1.190
(1.023, 1.385)0.0242 < 0.01 0.6025 Collected spot urine samples 5 0.892
(0.847, 0.939)< 0.0001 12.98 0.2670 0.922
(0.893, 0.952)< 0.0001 < 0.01 0.0744 Study quality ≤ 7 3 0.918
(0.852, 0.989)0.0241 0.01 0.7224 0.928
(0.887, 0.971)0.0012 < 0.01 0.8695 > 7 6 0.925
(0.826, 1.035)0.1743 55.12 0.1034 1.094
(0.909, 1.316)0.3439 84.39 0.0010 Adjusted blood pressure or hypertension Yes 4 0.883
(0.815, 0.958)0.0026 42.65 0.1638 0.921
(0.885, 0.959)0.0001 < 0.01 0.0365 No 5 0.967
(0.876, 1.068)0.5129 14.68 0.5758 1.084
(0.917, 1.281)0.3444 59.57 0.0211 Adjusted potassium excretion Yes 4 0.960
(0.873, 1.056)0.4035 < 0.01 0.6694 1.047
(0.879, 1.247)0.6076 40.92 0.1626 No 5 0.892
(0.829, 0.960)0.0023 36.53 0.1534 0.999
(0.855, 1.168)0.9923 92.71 0.0057 -
Based on the included studies, the dose-response meta-analysis was carried out. A significant non-linear relationship was found between sodium excretion and the risk of CV events (Pnon-linearity < 0.001) (Figure 3). In addition, the Wald test’s result showed that the two slopes in the non-linear model were significantly different (P < 0.001). We also excluded 5 studies using spot urine samples and performed a dose-response meta-analysis with the remaining 4 studies. The results showed that the sodium excretion and risk of CV events were associated linearly (P = 0.02) (Figure 4). The RR in the model showed that every 1 g increase in sodium excretion was associated with an increase in the risk of CV events up to 4% (RR: 1.04; 95% CI: 1.01, 1.07).
Figure 3. Non-linear dose-response association between 24-h Sodium excretion and the risk of CV events. Dashed lines indicated 95% confidence intervals. Reference standard was 1.265 g/24 h.
Figure 4. Linear dose-response association between 24-h Sodium excretion and the risk of CV events. Dashed lines indicated 95% confidence intervals.
None of the studies significantly affected the combined RR for sensitivity analysis in the low-level and high-level groups (Supplementary Figure S1 available in www.besjournal.com). In studies without an outcome of heart failure [10, 31, 34, 35], the combined RR for sensitivity analysis was 0.94 (95% CI: 0.86, 1.02) in the low-level group and 1.17 (95% CI: 0.91, 1.50) in the high-level group. When included in the study by Ma et al.[24], the combined RR was 0.95 (95% CI: 0.88, 1.04) in the low-level group and 1.07 (95% CI: 0.94, 1.23) in the high-level group.
-
The results of the funnel plots did not exclude any possible publication bias for the low-level and high-level groups (Supplementary Figure S2 available in www.besjournal.com). Neither the Egger’s nor Begg’s test detected any evidence of publication bias for the low-level group (P-value for Egger: 0.132; P-value for Begg: 0.252). The Egger’s test showed possible publication bias for the high-level group (P-value for Egger: 0.0006; P-value for Begg: 0.076).
doi: 10.3967/bes2022.119
24-Hour Urinary Sodium Excretion Association with Cardiovascular Events: A Systematic Review and Dose-Response Meta-Analysis
-
Abstract:
Objective The relationship between sodium intake and cardiovascular (CV) events remains unconfirmed. Therefore, we carried out a systematic review and dose-response meta-analysis for evaluating the potential impact of 24-hour sodium excretion on CV risk. Besides, 24-hour sodium excretion was used to replace daily sodium diet intake. Methods We searched ISI Web of Science, Embase, PubMed, and the Cochrane Library. Our study included cohort studies reporting hazard ratio (HR). The random-effects model was used for summarizing the total relative risks (RRs) between the included studies. In addition, the generalized least-squares regression was employed to fit the study model. Results A total of 9 studies involving 645,006 participants were included in this study. A significant non-linear relationship was observed between sodium excretion and CV events (Pnon-linearity < 0.001). In studies collecting 24-h urine samples, the sodium excretion and CV events risk were associated linearly (RR: 1.04; 95% CI: 1.01, 1.07). Conclusion In a linear dose-response manner, every 1 g increase in sodium intake was associated with an increased risk of CV events up to 4%. Further studies are required to validate our conclusions further. -
Key words:
- Cardiovascular events /
- Meta-analysis /
- 24-h urinary sodium excretion /
- Dose-response /
- Sodium intake
-
S1. PRISMA 2020 checklist
Section and topic Item Checklist item Location
where item
is reportedTITLE Title 1 Identify the report as a systematic review. 2 ABSTRACT Abstract 2 See the PRISMA 2020 for Abstracts checklist. 2 INTRODUCTION Rationale 3 Describe the rationale for the review in the context of existing knowledge. 2 Objectives 4 Provide an explicit statement of the objective(s) or question(s) the review addresses. 3 METHODS Eligibility criteria 5 Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. 3 Information sources 6 Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted. 3 Search strategy 7 Present the full search strategies for all databases, registers and websites, including any filters and limits used. 3 Selection process 8 Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. 3 Data collection process 9 Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. 3 Data items 10a List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect. 3 10b List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information. 3 Study risk of bias assessment 11 Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process. 4 Effect measures 12 Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results. 4 Synthesis methods 13a Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)). 13b Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions. 4 13c Describe any methods used to tabulate or visually display results of individual studies and syntheses. 4 13d Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. 4 13e Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression). 4 13f Describe any sensitivity analyses conducted to assess robustness of the synthesized results. 4 Reporting bias assessment 14 Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases). 4 Certainty assessment 15 Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. 4 RESULTS Study selection 16a Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram. 5 16b Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded. Study characteristics 17 Cite each included study and present its characteristics. 7–8 Risk of bias in studies 18 Present assessments of risk of bias for each included study. 5 Results of individual studies 19 For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots. 9, 11 Results of syntheses 20a For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies. 5 20b Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect. 9 20c Present results of all investigations of possible causes of heterogeneity among study results. 9 20d Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results. 11 Reporting biases 21 Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed. 12 Certainty of evidence 22 Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed. 11 DISCUSSION Discussion 23a Provide a general interpretation of the results in the context of other evidence. 12 23b Discuss any limitations of the evidence included in the review. 13 23c Discuss any limitations of the review processes used. 13 23d Discuss implications of the results for practice, policy, and future research. 13 OTHER INFORMATION Registration and protocol 24a Provide registration information for the review, including register name and registration number, or state that the review was not registered. 24b Indicate where the review protocol can be accessed, or state that a protocol was not prepared. 24c Describe and explain any amendments to information provided at registration or in the protocol. Support 25 Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review. Competing interests 26 Declare any competing interests of review authors. Availability of data, code and other materials 27 Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. Note. From: Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71.For more information, visit: http://www.prisma-statement.org/ Table 1. Characteristics of the included studies in this Meta-Analysis
Author, year Country Follow-up (years) Subjects/
events (n)Age (y) Gender Methods
of Na
measurementStudy population Outcome definition Martin J. O’Donnell, 2011[9] 40 countries 4.7 28,880/
4,72966.52 ±
7.22men/
womencollected morning fasting urine samples participants in ONTARGET and the TRANSCEND trials composite outcome (CV mortality, myocardial infarction, stroke, and hospitalization for CHF) Roman Pfister, 2013[32] the United Kingdom 12.9 19,857/
1,21058.0 ±
9.2men/
womencollected casual urine specimen general population heart failure Michel M. Joosten, 2013[31] the
Netherlands10.5 (IQR: 9.9−10.8) 7,543/
45228−75 men/
womencollected 24-h urine samples general population CHD was defined as incident cardiac morbidity and mortality (including myocardial infarction, acute and subacute ischemic heart disease, and coronary artery bypass grafting or percutaneous transluminal coronary angioplasty) Nancy R. Cook, 2014[10] the United States 5 2,312/
19331−50 men/
womencollected 24-h urine samples general population CVD or CVD death, including myocardial infarction, stroke, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, or death from cardiovascular disease Pamela Singer, 2014[12] the United States 18.6 3,505/
39952.4 ±
9.9men/
womencollected 24-h urine samples participants were individuals in a union-sponsored, worksite hypertension program in New York City between 1978 and 1999 coronary artery disease, including MI, ischemic heart disease, heart failure, and hypertensive heart disease Martin O’Donnell, 2019[14] 628 urban
and rural communities
in low, middle,
and high
income countries8.2 103,200/
7,88435−70 men/
womencollected morning fasting midstream urine sample general population the primary composite outcome was all caused mortality or myocardial infarction or stroke or heart failure Matti A. Vuori, 2020[33] Finland 14 4,517/
42445.4 ±
11.4men/
womencollected 24-h urine samples general population CVD was defined as the onset of CHD, stroke, or heart failure Wuopio J,
2020[35]the United Kingdom 8.2 ± 1.0 215,535/
3,75140−69 men collected midstream spot urine samples general population atrial fibrillation or atrial flutter 257,545/
2,221women Yi-Jie Wang, 2021[34] China 19.1 (IQR: 7.4−21.4) 2,112/
27954 ±
12men/
womenrecorded the sleep time and calculated the 24-h urine amount from sleep time and morning voiding urine general population Incident CVD events, including CHD and stroke Note. 24 h UNaE: 24 h urinary sodium excretion; CV: cardiovascular; CHD: coronary heart disease; CVD: cardiovascular disease; CHF: congestive heart failure; ONTARGET: Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial; TRANSCEND: Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease. Table 2. Subgroup analysis of different levels of sodium excretion and the risk of CV events
Subgroups No. of studies Low level High level Pooled RR (95% CI) P value I² (%) P value for
heterogeneityPooled RR (95% CI) P value I² (%) P value for
heterogeneityFollow-up duration < 10 years 4 0.910
(0.866, 0.958)0.0003 < 0.01 0.9611 0.926
(0.895, 0.957)< 0.0001 0.01 0.2904 > 10 years 5 0.947
(0.821, 1.093)0.4575 54.77 0.0481 1.093
(0.898, 1.329)0.3759 68.49 0.0037 Sample size < 10,000 5 1.027
(0.912, 1.156)0.6632 < 0.01 0.9789 1.228
(1.070, 1.410)0.0035 < 0.01 0.5886 > 10,000 4 0.886
(0.836, 0.940)0.0001 27.48 0.1930 0.918
(0.889, 0.948)< 0.0001 0.02 0.6090 Conducted in general population Yes 7 0.912
(0.843, 0.986)0.0207 42.63 0.1654 1.049
(0.902, 1.220)0.5358 91.08 0.0021 No 2 0.932
(0.834, 1.042)0.2162 < 0.01 0.4745 0.943
(0.861, 1.033)0.2062 < 0.01 0.7316 Method of urine collection Collected 24-h urine samples 4 1.042
(0.911, 1.192)0.5489 < 0.01 0.9721 1.190
(1.023, 1.385)0.0242 < 0.01 0.6025 Collected spot urine samples 5 0.892
(0.847, 0.939)< 0.0001 12.98 0.2670 0.922
(0.893, 0.952)< 0.0001 < 0.01 0.0744 Study quality ≤ 7 3 0.918
(0.852, 0.989)0.0241 0.01 0.7224 0.928
(0.887, 0.971)0.0012 < 0.01 0.8695 > 7 6 0.925
(0.826, 1.035)0.1743 55.12 0.1034 1.094
(0.909, 1.316)0.3439 84.39 0.0010 Adjusted blood pressure or hypertension Yes 4 0.883
(0.815, 0.958)0.0026 42.65 0.1638 0.921
(0.885, 0.959)0.0001 < 0.01 0.0365 No 5 0.967
(0.876, 1.068)0.5129 14.68 0.5758 1.084
(0.917, 1.281)0.3444 59.57 0.0211 Adjusted potassium excretion Yes 4 0.960
(0.873, 1.056)0.4035 < 0.01 0.6694 1.047
(0.879, 1.247)0.6076 40.92 0.1626 No 5 0.892
(0.829, 0.960)0.0023 36.53 0.1534 0.999
(0.855, 1.168)0.9923 92.71 0.0057 -
[1] WHO. World health statistics 2021: monitoring health for the SDGs, sustainable development goals. World Health Organization. 2021. [2] Benziger CP, Roth GA, Moran AE. The global burden of disease study and the preventable burden of NCD. Glob Heart, 2016; 11, 393−7. doi: 10.1016/j.gheart.2016.10.024 [3] Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 2002; 360, 1903−13. doi: 10.1016/S0140-6736(02)11911-8 [4] Stolarz-Skrzypek K, Kuznetsova T, Thijs L, et al. Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA, 2011; 305, 1777−85. doi: 10.1001/jama.2011.574 [5] Du XF, Fang L, Xu JW, et al. Association between 24-h urinary sodium and potassium excretion and blood pressure among Chinese adults aged 18-69 years. Sci Rep, 2021; 11, 3474. doi: 10.1038/s41598-021-83049-8 [6] Graudal N, Hubeck-Graudal T, Jürgens G, et al. Dose-response relation between dietary sodium and blood pressure: a meta-regression analysis of 133 randomized controlled trials. Am J Clin Nutr, 2019; 109, 1273−8. doi: 10.1093/ajcn/nqy384 [7] Appel LJ, Frohlich ED, Hall JE, et al. The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: a call to action from the American Heart Association. Circulation, 2011; 123, 1138−43. doi: 10.1161/CIR.0b013e31820d0793 [8] Umesawa M, Iso H, Date C, et al. Relations between dietary sodium and potassium intakes and mortality from cardiovascular disease: the Japan collaborative cohort study for evaluation of cancer risks. Am J Clin Nutr, 2008; 88, 195−202. doi: 10.1093/ajcn/88.1.195 [9] O'Donnell MJ, Yusuf S, Mente A, et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA, 2011; 306, 2229−38. [10] Cook NR, Appel LJ, Whelton PK. Lower levels of sodium intake and reduced cardiovascular risk. Circulation, 2014; 129, 981−9. doi: 10.1161/CIRCULATIONAHA.113.006032 [11] Kalogeropoulos AP, Georgiopoulou VV, Murphy RA, et al. Dietary sodium content, mortality, and risk for cardiovascular events in older adults: the Health, Aging, and Body Composition (Health ABC) Study. JAMA Intern Med, 2015; 175, 410−9. doi: 10.1001/jamainternmed.2014.6278 [12] Singer P, Cohen H, Alderman M. Assessing the associations of sodium intake with long-term all-cause and cardiovascular mortality in a hypertensive cohort. Am J Hypertens, 2015; 28, 335−42. doi: 10.1093/ajh/hpu141 [13] Prentice RL, Huang Y, Neuhouser ML, et al. Associations of biomarker-calibrated sodium and potassium intakes with cardiovascular disease risk among postmenopausal women. Am J Epidemiol, 2017; 186, 1035−43. doi: 10.1093/aje/kwx238 [14] O'Donnell M, Mente A, Rangarajan S, et al. Joint association of urinary sodium and potassium excretion with cardiovascular events and mortality: prospective cohort study. BMJ, 2019; 364, l772. [15] Campbell NRC, He FJ, Tan M, et al. The international consortium for quality research on dietary sodium/salt (TRUE) position statement on the use of 24-hour, spot, and short duration (< 24 hours) timed urine collections to assess dietary sodium intake. J Clin Hypertens, 2019; 21, 700−9. doi: 10.1111/jch.13551 [16] Lucko AM, Doktorchik C, Woodward M, et al. Percentage of ingested sodium excreted in 24-hour urine collections: a systematic review and meta-analysis. J Clin Hypertens, 2018; 20, 1220−9. doi: 10.1111/jch.13353 [17] McLean RM. Measuring population sodium intake: a review of methods. Nutrients, 2014; 6, 4651−62. doi: 10.3390/nu6114651 [18] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg, 2010; 8, 336−41. doi: 10.1016/j.ijsu.2010.02.007 [19] Hamling J, Lee P, Weitkunat R, et al. Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Stat Med, 2008; 27, 954−70. doi: 10.1002/sim.3013 [20] WHO. Guideline: sodium intake for adults and children. WHO. 2012. [21] DeSalvo KB, Olson R, Casavale KO. Dietary guidelines for americans. JAMA, 2016; 315, 457−8. doi: 10.1001/jama.2015.18396 [22] Powles J, Fahimi S, Micha R, et al. Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide. BMJ Open, 2013; 3, e003733. doi: 10.1136/bmjopen-2013-003733 [23] Ades AE, Lu G, Higgins JPT. The interpretation of random-effects meta-analysis in decision models. Med Decis Making, 2005; 25, 646−54. doi: 10.1177/0272989X05282643 [24] Ma Y, He FJ, Sun Q, et al. 24-hour urinary sodium and potassium excretion and cardiovascular risk. N Engl J Med, 2022; 386, 252−63. doi: 10.1056/NEJMoa2109794 [25] Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ, 2003; 327, 557−60. doi: 10.1136/bmj.327.7414.557 [26] Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997; 315, 629−34. doi: 10.1136/bmj.315.7109.629 [27] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics, 1994; 50, 1088−101. doi: 10.2307/2533446 [28] Orsini N, Li RF, Wolk A, et al. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol, 2012; 175, 66−73. doi: 10.1093/aje/kwr265 [29] Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol, 1992; 135, 1301−9. doi: 10.1093/oxfordjournals.aje.a116237 [30] Harre FE Jr, Lee KL, Pollock BG. Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer Inst, 1988; 80, 1198−202. doi: 10.1093/jnci/80.15.1198 [31] Joosten MM, Gansevoort RT, Mukamal KJ, et al. Sodium excretion and risk of developing coronary heart disease. Circulation, 2014; 129, 1121−8. doi: 10.1161/CIRCULATIONAHA.113.004290 [32] Pfister R, Michels G, Sharp SJ, et al. Estimated urinary sodium excretion and risk of heart failure in men and women in the EPIC-Norfolk study. Eur J Heart Fail, 2014; 16, 394−402. doi: 10.1002/ejhf.56 [33] Vuori MA, Harald K, Jula A, et al. 24-h urinary sodium excretion and the risk of adverse outcomes. Ann Med, 2020; 52, 488−96. doi: 10.1080/07853890.2020.1780469 [34] Wang YJ, Chien KL, Hsu HC, et al. Urinary sodium excretion and the risk of CVD: a community-based cohort study in Taiwan. Br J Nutr, 2022; 127, 1086−97. doi: 10.1017/S0007114521001768 [35] Wuopio J, Orho-Melander M, Ärnlöv J, et al. Estimated salt intake and risk of atrial fibrillation in a prospective community-based cohort. J Intern Med, 2021; 289, 700−8. doi: 10.1111/joim.13194 [36] Jayedi A, Ghomashi F, Zargar MS, et al. Dietary sodium, sodium-to-potassium ratio, and risk of stroke: a systematic review and nonlinear dose-response meta-analysis. Clin Nutr, 2019; 38, 1092−100. doi: 10.1016/j.clnu.2018.05.017 [37] Graudal N, Jürgens G, Baslund B, et al. Compared with usual sodium intake, low- and excessive-sodium diets are associated with increased mortality: a meta-analysis. Am J Hypertens, 2014; 27, 1129−37. doi: 10.1093/ajh/hpu028 [38] Wang YJ, Yeh TL, Shih MC, et al. Dietary sodium intake and risk of cardiovascular disease: a systematic review and dose-response meta-analysis. Nutrients, 2020; 12, 2934. doi: 10.3390/nu12102934 [39] Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension, 1996; 27, 481−90. doi: 10.1161/01.HYP.27.3.481 [40] Lother A, Fürst D, Bergemann S, et al. Deoxycorticosterone acetate/salt-induced cardiac but not renal injury is mediated by endothelial mineralocorticoid receptors independently from blood pressure. Hypertension, 2016; 67, 130−8. doi: 10.1161/HYPERTENSIONAHA.115.06530 [41] Visser FW, Boonstra AH, Lely AT, et al. Renal response to angiotensin II is blunted in sodium-sensitive normotensive men. Am J Hypertens, 2008; 21, 323−8. doi: 10.1038/ajh.2007.63 [42] Patel Y, Joseph J. Sodium intake and heart failure. Int J Mol Sci, 2020; 21, 9474. doi: 10.3390/ijms21249474 [43] O'Donnell M, Mente A, Rangarajan S, et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med, 2014; 371, 612−23. doi: 10.1056/NEJMoa1311889 [44] Cook NR, Obarzanek E, Cutler JA, et al. Joint effects of sodium and potassium intake on subsequent cardiovascular disease: the trials of hypertension prevention follow-up study. Arch Intern Med, 2009; 169, 32−40. doi: 10.1001/archinternmed.2008.523 [45] Wen XX, Zhou L, Stamler J, et al. Agreement between 24-h dietary recalls and 24-h urine collections for estimating sodium intake in China, Japan, UK, USA: the international study of macro- and micro-nutrients and blood pressure. J Hypertens, 2019; 37, 814−19. doi: 10.1097/HJH.0000000000001941 [46] He FJ, Ma Y, Campbell NRC, et al. Formulas to estimate dietary sodium intake from spot urine alter sodium-mortality relationship. Hypertension, 2019; 74, 572−80. doi: 10.1161/HYPERTENSIONAHA.119.13117 [47] Cappuccio FP, Beer M, Strazzullo P, et al. Population dietary salt reduction and the risk of cardiovascular disease. A scientific statement from the European salt action network. Nutr Metab Cardiovasc Dis, 2019; 29, 107−14. [48] Flegal KM, Keyl PM, Nieto FJ. Differential misclassification arising from nondifferential errors in exposure measurement. Am J Epidemiol, 1991; 134, 1233−44. doi: 10.1093/oxfordjournals.aje.a116026 [49] Poggio R, Gutierrez L, Matta MG, et al. Daily sodium consumption and CVD mortality in the general population: systematic review and meta-analysis of prospective studies. Public Health Nutr, 2015; 18, 695−704. doi: 10.1017/S1368980014000949 -
21500Supplementary Materials.pdf